Behind the science
‘Long-acting therapies are no longer the future of HIV treatment – they are the now’
Innovation has transformed the prospects of people living with HIV from a death sentence to a chronic, manageable condition. In this article, Dr. Kimberly Smith, Head of R&D at ViiV Healthcare – GSK’s specialist HIV company – explains just how far her team’s ambitions go.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.